NEW YORK, Dec. 18, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on ALGN, KTWO, NUVA, and NXTM which is a click away at www.wallstequities.com/registration. On Friday, December 15, 2017, the NASDAQ Composite ended the trading
San Jose, California headquartered Align Technology Inc.'s stock finished Friday's session 0.11% lower at $233.55 with a total trading volume of 1.64 million shares, which was above its three months average volume of 1.10 million shares. The Company's shares have advanced 24.00% in the previous three months, 132.92% over the past twelve months, and 142.95% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.79% and 38.74%, respectively. Additionally, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing digital services, have a Relative Strength Index (RSI) of 47.09.
On December 08th, 2017, research firm Deutsche Bank initiated a 'Hold' rating on the Company's stock, with a target price of $250 per share. Signing up now gives you access to the free research coverage on ALGN at:
K2M Group Holdings
On Friday, shares in Leesburg, Virginia headquartered K2M Group Holdings Inc. recorded a trading volume of 680,225 shares, which was above its three months average volume of 495.18 thousand shares. The stock ended the session 3.57% higher at $18.00. The stock is trading below its 50-day moving average by 5.11%. Moreover, shares of K2M Group, which focuses on designing, developing, and commercializing spine and minimally invasive solutions in the US and internationally, have an RSI of 44.48.
On December 08th, 2017, research firm Needham downgraded the Company's stock rating from 'Strong Buy' to 'Buy' while revising its previous target price from $26 a share to $20 a share. Get access to our top-rated research, including the free report on KTWO at:
San Diego, California headquartered NuVasive Inc.'s shares closed the day 2.03% higher at $60.79. The stock recorded a trading volume of 1.28 million shares, which was above its three months average volume of 1.10 million shares. The Company's shares have gained 9.14% in the last month. The stock is trading above its 50-day moving average by 7.95%. Additionally, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 67.56. Click here to subscribe for a free membership which welcomes you with our report on NUVA at:
Shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. finished 0.74% higher at $26.02. The stock recorded a trading volume of 718,835 shares, which was above its three months average volume of 596.17 thousand shares. The Company's shares have advanced 1.28% over the last twelve months. The stock is trading below its 50-day moving average by 1.92%. Furthermore, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 48.66. Join our big investor community at Wall St. Equities today and start so with your free report on NXTM at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-medical-equipments-investors----align-technology-k2m-group-nuvasive-and-nxstage-medical-300572463.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All